


MSD® Human Eotaxin-2 Kit



For quantitative determination in human serum and plasma



1. Eotaxin-2
2. BSA blocked
3. BSA blocked
4. BSA blocked



MSD MULTI-SPOT®
96-Well 4-Spot Plate



Eotaxin-2 (CCL24) is a C-C chemokine attractant for eosinophils, basophils, and Th2 lymphocytes.^{1,2} As part of the eotaxin family, Eotaxin-2 is specific for receptor CCR3, which also binds ligands RANTES, MCP-3, and MCP-4.¹ Eotaxin and eotaxin-2 are both strongly attractive to eosinophils and are likely critical in eosinophilic recruitment, activation, and degranulation.^{2,3}

Eotaxin-2's chemotactic effect on eosinophils implicates it in allergic reactions and asthma^{2,4} but does not preclude its involvement in other immune responses, such as arthritis,¹ or in colorectal cancer.⁵ Localized eosinophil accumulations are directly correlated to eotaxin-2 dosage concentration^{3,4} and are independent of the allergic status of the subject.³ Eotaxin-2 expression is also found in abundance in primary colorectal cancer and colorectal liver metastases, which when compared to normal tissue expression, hints at a role in tumor environment priming and conditioning.⁵

The assay is available on 96-well, 4-spot plates. Representative data from the assay is presented below.


Alzheimer's Disease
BioProcess
Cardiac
Cell Signaling
Clinical Immunology
Cytokines
Growth Factors
Hypoxia
Immunogenicity
Inflammation
Metabolic
Oncology
Toxicology
Vascular

Catalog Numbers

Human Eotaxin-2 Kit	
Kit Size	Catalog #
1 plate	K151RKD-1
5 plates	K151RKD-2
25 plates	K151RKD-4

Assay Sensitivity

The following standard curve illustrates the dynamic range of the Human Eotaxin-2 assay.



Eotaxin-2	
Average LLOD (pg/mL)	0.10

The lower limit of detection (LLOD) is a calculated concentration based on a signal 2.5 standard deviations above the background (zero calibrator blank).

Ordering Information

MSD Customer Service
Phone: 1-301-947-2085
Fax: 1-301-990-2776
Email: CustomerService@mesoscale.com

MSD Advantage

- **Multiplexing:** Multiple analytes can be measured in one well using typical sample volumes of 25 µL or less without compromising speed or performance
- **Large dynamic range:** Linear range of up to five logs enables the measurement of native levels of biomarkers in normal and diseased samples without multiple dilutions
- **Minimal background:** The stimulation mechanism (electricity) is decoupled from the response (light signal), minimizing matrix interference
- **Simple protocols:** Only labels bound near the electrode surface are excited, enabling assays with fewer washes
- **Flexibility:** Labels are stable, non-radioactive, and conveniently conjugated to biological molecules
- **High sensitivity and precision:** Multiple rounds of label excitation and emission enhance light levels and improve sensitivity

Company Address

MESO SCALE DISCOVERY®
A division of
Meso Scale Diagnostics, LLC.
1601 Research Boulevard
Rockville, MD 20850 USA

www.mesoscale.com®

For Research Use Only.
Not for use in diagnostic
procedures.

For a complete list of products, please visit our website at www.mesoscale.com.

MSD Cytokine Assays

References

1. Ablin JN, et al. Protective effect of Eotaxin-2 inhibition in adjuvant-induced arthritis. *Clin Exp Immunol*. 2010 Aug;161(2):276-83.
2. Ochkur SI, et al. Coexpression of IL-5 and Eotaxin-2 in mice creates an eosinophil-dependent model of respiratory inflammation with characteristics of severe asthma. *J Immunol*. 2007 Jun 15;178(12):7879-89.
3. Menzies-Gow A, et al. Eotaxin (CCL11) and Eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. *J Immunol*. 2002 Sep 1;169(5):2712-8.
4. Olze H, et al. Eosinophilic nasal polyps are a rich source of Eotaxin, Eotaxin-2, and Eotaxin-3. *Rhinology*. 2006 Jun;44(2):145-50.
5. Cheadle EJ, et al. Eotaxin-2 and colorectal cancer: a potential taret for immune therapy. *Clin Cancer Res*. 2007 Oct 1;13(19):5719-28.

MESO SCALE DISCOVERY, MESO SCALE DIAGNOSTICS, DISCOVERY WORKBENCH, MULTI-ARRAY, MULTI-SPOT, QUICKPLEX, SECTOR PR, SECTOR, SECTOR HTS, SULFO-TAG, www.mesoscale.com, SMALL SPOT (design), 96 WELL 1, 4, 7, & 10-SPOT (designs), 384 WELL 1 & 4-SPOT (designs), MSD, MSD (design), and SPOT THE DIFFERENCE are trademarks and/or service marks of Meso Scale Diagnostics, LLC.

© 2012 Meso Scale Diagnostics, LLC. All rights reserved.

